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ABSTRACT
Introduction Middle East and North Africa (MENA) has a 
rising rate of new HIV infections and AIDS- related mortality. 
Consistent adherence to antiretroviral therapy (ART) leads 
to viral suppression, preventing HIV transmission and 
treatment failure. mHealth interventions can improve ART 
adherence by providing tailored support and directing 
patients to existing healthcare services. HamRaah 
(Persian for ‘together- in- path’) is the first mHealth- 
based intervention in a MENA country and is designed to 
improve adherence through two- way mobile messaging 
for people recently diagnosed with HIV in Tehran, Iran. The 
objectives of this pilot randomised controlled trial (RCT) 
are to examine the feasibility, acceptability and preliminary 
effectiveness of HamRaah, and to develop an explanatory 
theory for any observed effects through a nested realist 
evaluation.
Methods A feasibility study and two- arm RCT of 
HamRaah, with an embedded realist evaluation will 
be conducted. Participants will be randomised 1:1 to 
HamRaah or routine care for a 6- month intervention. The 
initial effectiveness of HamRaah will be assessed through 
the primary outcome of self- reported ART adherence and 
several secondary outcomes: retention in care, CD4 count 
and viral suppression. A theory- driven realist evaluation 
framework will be used to develop an explanatory theory 
regarding what works, for whom, how and in what 
context.
Ethics and dissemination The study received ethical 
clearance from Tehran University of Medical Sciences 
Ethics Committee and Oxford Tropical Research Ethics 
Committee People living with HIV in Tehran and key 
country stakeholders in HIV policy and programming have 
been involved in the development of HamRaah and this 
pilot trial. Participants will provide informed consent prior 
to study enrolment. The results will be disseminated to 
all stakeholders and presented in peer- reviewed journal 
publications and conferences.
Trial registration number IRCT20100601004076N23; 
Pre- results.
INTRODUCTION
Despite the expansion of antiretroviral 
therapy (ART), countries in the Middle East 
and North Africa (MENA) region continue 
to show an increasing rate of new HIV infec-
tions and AIDS- related mortality.1 Only 
32% of people living with HIV (PLHIV) are 
virally suppressed, compared with 59% glob-
ally.1 2 Consistent ART adherence promotes 
viral suppression and maximises the benefits 
of treatment as prevention,3 which is essential 
for both PLHIV and the public. Conversely, 
non- adherence is a major contributor to poor 
viral suppression,4–7 ultimately leading to 
treatment failure8 and increasing morbidity 
Strengths and limitations of this study
 ► This pilot randomised controlled trial of mHealth for 
adherence to antiretroviral therapy is the first of its 
kind in a Middle East and North Africa (MENA) coun-
try. It addresses an important evidence gap with re-
gards to the feasibility, acceptability and potential for 
impact of a tailored mHealth approach within MENA.
 ► The study uses triangulation of quantitative, qual-
itative, and realist data to produce complimentary 
findings and a deeper understanding of the role of 
context.
 ► Patients and public stakeholders were consulted in 
the design of the mHealth intervention, and in trial 
planning and implementation.
 ► This pilot study is designed to provide an initial 
estimate of effect size, but may have insufficient 
statistical power to detect differences in outcomes 
between groups.
 ► The intervention period will be relatively short, lim-
iting the capacity to show long- term effects that 
might accumulate over time.
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and mortality.9 10 Thus, programmes are needed to 
support PLHIV who are receiving ART, to achieve consis-
tently high adherence to daily medication regimens.11–15
Over the past two decades of ART expansion, a variety of 
adherence interventions have been tested and shown to 
be effective and sustainable in both high- resource and low- 
resource settings.16 17 Interventions that build on existing 
healthcare infrastructure and leverage available resources 
to support PLHIV are particularly useful.18 A promising 
strategy involves interventions delivered through mobile 
and digital platforms. Rather than devoting additional 
resources for conventional programmes, connecting 
PLHIV digitally to existing programmes can potentially 
support ART adherence with increased personalisa-
tion and scale at a lower cost.19–21 WHO recommends 
mHealth strategies for improving ART adherence,22 but 
emphasises that mHealth interventions are better suited 
to support rather than replace health services,18 and high-
lights the need for tailored and differentiated models of 
care delivery.23
HIV differentially affects key population groups, such 
as people who inject drugs (PWID), sex workers and their 
clients, men who have sex with men, transgendered indi-
viduals and the general population.24 This heterogeneity 
of the HIV epidemic has propelled a paradigm shift, 
calling for differentiated care models to manage HIV.23 25 
Moreover, in dealing with highly vulnerable segments of 
the population, experts caution against transporting 
interventions across groups, regions and countries, and 
recommend interventions that fit regional, national 
and local contexts.26 27 This concern is especially salient 
with regards to the MENA region, where high levels 
of HIV- related stigma and discrimination28 29 require 
programmes to respect privacy concerns. Moreover, the 
current COVID-19 pandemic necessitates minimising 
hospital visits and increasing remote service delivery. 
Digital interventions, with their potential for increased 
personalisation and privacy, can offer remote and differ-
entiated HIV care suited for the MENA context, provided 
that PLHIV have personal access to mobile phones, and 
that providers can ensure data security. There is, however, 
a dearth of evidence on interventions that have been 
adapted and tested specifically for MENA countries. 
Thus, interventions with fidelity to the evidence- base and 
adaptation to this specific context are needed.
In response to this need, and for the first time in a 
MENA country, this study aims to examine the feasibility, 
acceptability and preliminary effectiveness of an mHealth 
intervention in Tehran, Iran, with an emphasis on the role 
of context to discover how, for whom, and why the inter-
vention works (or not), using a nested realist approach.30 
Home to 29% of all cases in the MENA region,1 HIV prev-
alence in Iran is estimated at 0.05%.31–33 As opposed to 
the rest of MENA, the rate of new HIV infections in Iran 
has declined by 12% since 2010. This improvement could 
be attributable to the healthcare infrastructure, which 
provides access to methadone replacement therapy, 
needle exchange programmes, free and universal access 
to ART at the point of diagnosis, and peer- run adherence 
clubs to support PLHIV throughout every province in 
the country. This combination of services provides the 
optimal setting for an mHealth intervention that lever-
ages existing healthcare capacities.34 35 By 2018, Iranians 
had been assigned over 169.5 million SIM cards, of 
which 88 million were actively in use for a population of 
81.8 million,36 thus making text- messaging a widely acces-
sible form of communication. Smartphone use has also 
rapidly increased over the past 3 years, and the country 
is now 11th in the world in terms of smartphone pene-
tration rate.37 Iran is also severely hit by the COVID-19 
pandemic within the MENA region, further necessitating 
the assessment of healthcare approaches that minimise 
physical hospital visits. Thus, mHealth interventions 
that offer remote support, safely and effectively, could 
be a promising approach to address the challenges of 
managing HIV.
HIV epidemic in Iran
The HIV epidemic in Iran was initially interwoven with 
the injection drug use epidemic, but currently incidence 
is mainly driven by sexual transmissions.38 Recently, the 
epidemic burden is shifting from men to women. Before 
2017, 65.8% of transmissions occurred through the use 
of shared needles by PWID, the largest key PLHIV, while 
sexual and vertical transmissions accounted for 19.6% 
and 1.5% of all cases, respectively. Since 2017, 47% of 
cases were sexually transmitted, followed by 32% of cases 
of transmission through injection. The total proportion 
of women diagnosed with HIV increased from 4.7% of all 
cases in 2001 to 16% in 2017.34 39 40 Iran provides universal 
and free access to ART through a decentralised model of 
health delivery across 31 provinces via university hospi-
tals, operating under the joint Ministry of Health and 
Medical Education, providing uniform services for HIV, 
such as voluntarily, counselling and testing (VCT) centres 
and Positive Clubs.
Intervention rationale
Two- way communication approaches appear to have 
important benefits for improving ART adherence and 
achieving viral suppression. WelTelKenya41 was the first 
study supporting PLHIV through weekly text- message 
check- ins, and in a similar study in Uganda,42 weekly, but 
not daily, communication improved adherence. Meta- 
analyses corroborate that two- way and weekly messaging 
interventions appear more effective and less burden-
some than daily one- way reminders.43 44 Moreover, recent 
studies show that mobile messaging may not be effective 
for PLHIV starting second- line therapy as a result of non- 
adherence,45 46 suggesting that mHealth interventions 
may be more effective when implemented at the onset of 
ART to promote better habit formation47 and improved 
long- term outcomes, although the long- term effective-
ness has not been studied beyond a year.
HamRaah (Persian for ‘together- in- path’) is a two- way 
mobile messaging intervention, depicted in figure 1, for 
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recently diagnosed PLHIV in Tehran, Iran. An initial 
qualitative study investigated the Iranian context in 
which HIV is managed. The findings (currently under 
review for publication) signified that high levels of stigma 
and discrimination lead to loss of hope and motivation 
to adhere, especially within the first year following diag-
nosis, when navigation of the health system and access to 
available resources is also unfamiliar. During this period, 
mHealth interventions can make PLHIV feel cared for by 
offsetting depressed mood,47 and increase motivation for 
adherence through positive reinforcement.23 Moreover, 
by providing an efficient means of connecting patients 
to needed care before they reach a critical clinical stage, 
either from non- adherence or untreated comorbidities, 
such interventions may reduce mortality and save costs 
for the health system.25
AIMS AND OBJECTIVES
The current pilot study’s overarching aims are to examine 
HamRaah’s: (1) trial feasibility and intervention accept-
ability, (2) initial effectiveness and (3) explanatory theory. 
The specific objectives are as follows:
1. Assess the feasibility of recruitment, randomisation, 
allocation concealment and blinding procedures for 
outcome assessment.
2. Determine the acceptability of HamRaah intervention 
by participants and fidelity to protocol by counsellor.
3. Determine preliminary effects of the pilot intervention 
on the primary outcome of adherence to ART.
4. Conduct a nested realist evaluation to refine an explan-
atory programme theory with enriched evidence on 
what works, for whom, how and in what circumstances.
5. Triangulate realist, qualitative and quantitative find-
ings in a sequential approach to investigate mediating 
relationships.
Reporting in this protocol is based on the Standard 
Protocol Items: Recommendations for Interventional 
Trials checklist for recommended items in a trial protocol.
METHODS AND ANALYSIS
Overview of study design
The feasibility and acceptability study relate to proce-
dural uncertainties of the trial and the acceptability of 
HamRaah. These aspects will be examined via quan-
titative and qualitative data, collected throughout the 
implementation process and at the conclusion of the trial 
through checklists, spreadsheets, focus group discussions 
(FGDs) and interviews. The perspectives of HamRaah 
participants, counsellor and project staff will be collected 
to answer the feasibility and acceptability questions that 
could inform a future definitive trial.
The HamRaah pilot consists of:
 ► Arm1: routine care +HamRaah.
 ► Arm2: routine care.
Participants will be assigned through permutated even- 
number blocks to be randomised in a 1:1 ratio to arm 1 
or arm 2. The intervention period is 6 months for each 
participant in arm 1, with equivalent follow- up for partici-
pants in arm 2. Figures 1 and 2 represent the intervention 
and messaging protocol respectively. The initial effective-
ness of HamRaah will be assessed through self- reported 
ART adherence, as a primary outcome, and retention in 
Figure 1 HamRaah intervention protocol. IKHC, Imam 
Khomeini Hospital Complex. Figure 2 HamRaah Weekly messaging protocol, C: 
Counsellor, P: participant, red responses will trigger a phone 
call.
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routine clinical care, immune reconstitution and viral 
suppression, as secondary outcomes. Figure 3 provides 
the study design, flow, criteria for selection of participants 
and outcome assessment points.
The nested realist evaluation will be informed by 
HamRaah participants through mechanistic thinking, 
which aims to develop an explanatory theory of how and 
why HamRaah may work (or not).30 48 Thus, the focus 
of the nested realist intervention will be to recognise 
which aspects of the study context are changed through 
HamRaah, and how this change could alter participants’ 
reasoning, triggering a new mechanism and producing 
an observed outcome, explained in a refined theory.
Research setting
The study will be conducted in the infectious diseases unit 
of the Imam Khomeini Hospital Complex (IKHC), which 
is the teaching hospital of Tehran University of Medical 
Sciences (TUMS) and based in the sociodemographi-
cally diverse city centre of Tehran. IKHC houses Tehran’s 
central VCT centre, where the study participants will be 
recruited from the VCT’s more than 4000 patients and 
an average of 15 new cases of monthly HIV diagnosis. A 
peer- run Positive Club at IKHC offers peer- delivered coun-
selling and psychosocial support for PLHIV who need 
additional care. IKHC also houses the Iranian Research 
Centre for HIV/AIDS (IRCHA)—the main collaborating 
research partner of this project—with a team of eight full- 
time researchers and research assistants, from which the 
staff for this project are recruited. For additional informa-
tion see online supplemental appendix 1.
Routine care
Routine care offered at the VCT centres consists of an 
initial general counselling session at the time of diag-
nosis. Medication pick- up is initially set at a monthly 
interval, and as patients collect medications regularly, 
and appear to be adhering well, the window for collection 
is extended to every 2 months. However, as a result of the 
recent pandemic, this time frame has been extended to 
reduce patient visits to the hospital, now collecting their 
medications every 3–6 months, while some receive their 
medications via motorcycle delivery system. For addi-
tional information see online supplemental appendix 1.
HamRaah intervention
HamRaah is a weekly mobile messaging interven-
tion, based on the WelTel model,41 49 which serves as a 
counsellor- initiated check- in with recently diagnosed 
PLHIV to assess adherence and physical and mental well- 
being in the past week. Figure 1 depicts the key features 
of the HamRaah protocol, which are offered in addition 
to the routine care outlined above. HamRaah recipients 
will be contacted by text message on a weekly basis by a 
counsellor to enquire about their well- being and adher-
ence to ART. The counsellor specifically asks PLHIV how 
many (if any) days they missed their doses, and what (if 
any) problems they may be facing. If contacted, PLHIV 
do not respond to the messages, or report back on 
missing doses or facing challenges, a follow- up contact by 
live phone call will be made to assess the patient’s current 
needs. Figure 2 is a pictorial representation of the weekly 
messaging protocol. For additional information see 
online supplemental appendix 1.
Research population
Newly identified PLHIV, enrolled under care at the VCT 
centre, will be eligible to participate if they meet the 
following criteria: (1) are aged 18 years or above; (2) 
are treatment naïve, defined as starting ART within the 
6 months; (3) own or have access to a mobile phone; (4) 
are able to operate a cell phone to communicate using 
mobile- messaging (help by a partner is sufficient for 
patients with reading and/or writing difficulties); (5) 
consent to be contacted through mobile communication 
to receive HIV- and ART- related information. Figure 3 
depicts the selection and flow of participants through the 
study.
Sample size
This study is designed as a pilot. The target sample size 
of 58 is based on the number needed to detect a 20% 
improvement in the primary outcome of mean adher-
ence, which will be measured as a continuous variable 
based on the number of missed doses. Our calculations 
were estimated using PS software by Vanderbilt Univer-
sity, and assumed a 75% baseline estimate of adherence, 
based on clinician estimations from pharmacy refill data, 
with 90% power and a two- sided alpha of 0.05; we also 
allowed for 10% attrition. However, the clinical signifi-
cance of any observed improvement will depend on the 
baseline level of adherence, and smaller effects, observed 
within the range of 5%–10%, would also be suggestive of 
impact to be assessed in a fully powered study.
Figure 3 Study design. ART, antiretroviral therapy; VCT, 
voluntarily, counselling and testing.
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Participant recruitment
Study recruitment began in August of 2019 and has 
faced delays due to the COVID-19 pandemic. Partic-
ipants are identified from the list of HIV patients, who 
are diagnosed within the past 6 months and meet eligi-
bility criteria. The IRCHA, where the research team is 
based, is located within the same hospital complex. All 
staff members conducting the recruitment and informed 
consent process are recruited from IRCHA, trained in 
the ethical treatment of human participants, and familiar 
with informed consent guidelines. To maximise recruit-
ment, two approaches will be used:
i. Direct, which involves obtaining contact information 
of the recently diagnosed PLHIV and contacting 
them via telephone to invite them to participate.
ii. Indirect, which involves a brief introduction during 
individual clinic visits.
Patients who show initial interest will be asked to visit 
IRCHA to receive further information about the trial and 
provide informed consent.
Randomisation and blinding
Randomisation procedures follows a permutated block 
technique, which occurs after baseline data collection. R 
software is utilised by a researcher in Oxford to produce 
a set of randomly generated assignments through permu-
tated even- number block sizes that will randomise in a 1:1 
ratio to HamRaah or routine care. A study team member 
in Tehran allocates participants to intervention and 
comparison groups based on the order of completing 
the informed consent forms, and the predetermined 
assignments received from the researcher in Oxford. This 
process reduces the potential for allocation bias through 
correct sequence generation. Researchers will notify each 
participant individually about his/her allocation.
Given the mHealth nature HamRaah, participants 
and intervention facilitators cannot be blinded to group 
assignments. Similarly, researchers conducting the nested 
realist evaluation will be aware of participant assignments. 
To mitigate against interviewer bias, participants will be 
encouraged to complete the questionnaires online. In 
cases where participants need assistance in completing 
the questionnaires, interviewer bias will be minimised 
by keeping the interviewers blinded to the group alloca-
tions of the participants. Any incident of unblinding will 
be recorded and the interviewer’s knowledge regarding 
group assignment will be documented.
Data collection
Quantitative data for efficacy outcomes will be collected 
via Research Electronic Data Capture (REDCap) at base-
line and at the end of the 6- month intervention. Partic-
ipants can choose to complete and submit the forms 
within the privacy of their homes on their mobile phones, 
tablets or computers. For PLHIV who need assistance in 
completing the survey, research assistants will arrange an 
appointment to guide them through the process using a 
computer at IRCHA. Should a participant prefer to stay 
at home, the research assistant will provide guidance 
over the phone. For participants who prefer not to fill in 
online questionnaires, a paper questionnaire option will 
also be available.
Qualitative data, for the realist evaluation and for 
the acceptability study, will draw on the perspectives 
of HamRaah participants, lead counsellor and other 
providers for care to participants referred from HamRaah. 
The research method will involve interviews and FGDs, 
both of which allow researchers to explore areas of 
interest. Individual interviews allow an in- depth explora-
tion of personal and sensitive topics, while focus groups 
involve group interactions with the possibility of creating 
a trusted environment among peers.50 Qualitative data 
collection occurs at the conclusion of the 6- month inter-
vention for participants. The initial target is to conduct 
five small FGDs (5–7 participants each), and 12 individual 
interviews (including providers). However, recruitment 
for focus groups and individual interviews will continue 
until data saturation is reached, or until all who received 
6 months of HamRaah have been interviewed.
Data collection for quantitative surveys will end by May 
of 2021. The post- trial qualitative acceptability assess-




Feasibility outcomes of interest, relating to methodolog-
ical and procedural uncertainties, are listed in table 1.
Primary outcome
Adherence to ART
The primary outcome of the pilot trial is adherence to 
daily ART, which will be measured as a continuous vari-
able of self- reported adherence using the Wilson three- 
item self- report scale on adherence.51 The scale will 
measure the number of missed doses in the past 30 days.
Secondary outcomes
Retention in care
Retention in care will be measured as visit constancy for 
monthly (or bimonthly) appointments. Evidence suggests 
that there is no gold standard tool to measure reten-
tion in care and selection of approach must be tailored 
to context.52 Larger windows for pick up are generally 
reserved for adherent patients; however, in the current 
context of the COVID-19 pandemic, medications are 
either being delivered to patients, or given for a longer 
period of time. As such, measuring the percentage 
of expected visits that were attended, within a 1- week 
window, accommodates the variability in scheduling as a 
result of personal or COVID-19- related reasons.
Clinical measures
The clinical measures of immune reconstitution (CD4 
>500/µL)53 and viral suppression (mRNA <200 copies/
µL)53 will be assessed through change of CD4 cell 
counts from baseline; however, it is unlikely to observe 









pen: first published as 10.1136/bm




6 Ameli V, et al. BMJ Open 2021;11:e042296. doi:10.1136/bmjopen-2020-042296
Open access 
an effect, given the short duration of the trial. Viral load 
tests are not included in the free national antiretroviral 
programme, and are offered in this trial as a benefit of 
participation at the conclusion of the trial; consequently, 
virologic suppression is measured at a single time point.
Psychosocial measures, treatment barriers and demo-
graphic factors are measured through the questionnaires 
listed in table 2. These measurements will inform the 
study as they could be impacted by the intervention, or 
act as a mediator or moderator. The study is not powered 
Table 2 Trial measurements
Outcome measures Baseline 6 Months
Adherence to ART Wilson 3- item self- report scale on adherence51   √
Retention in care Missed visits and monthly visit constancy52   √
Viral load Virological suppression (<200 copies/μL)53   √
CD4 cell count Immune reconstitution, (>500/µL)53   √
Depression Patient Health Questionnaire-956 √ √
Anxiety Hospital Anxiety and Depression Scale57 58 √ √
Social support Multidimensional Scale Perceived Social Support59 √ √
Stigma and disclosure The Berger stigma scale shortened and validated60 √ √
Coping Coping responses61 √ √
Drug use WHO- ASSIST62 √ √
Beliefs Concerns and beliefs on ART necessity63 √ √
Barriers Structural barriers to clinic attendance for ART patients64 √ √
Demographic factors Age, gender, education, marital status, housing, household 
size, employment, income and poverty. These items are picked 
from Iranian Ministry of Health’s demographic questionnaire.
√ √
ART, antiretroviral therapy.
Table 1 Feasibility measurements
Variables Measure
Mode of
administration Weekly Monthly 24 weeks
Recruitment55 No of subjects enrolled per month Spreadsheet*   √   
No of recruitment calls made per enrolee Spreadsheet*   √   
Proportion of new PLHIV successfully 
reached
Spreadsheet*   √   
Proportion of new PLHIV enrolled and 
randomised
Spreadsheet*   √   
Randomisation Balance achieved across two arms Analysis†     √
Retention Proportion of participants with complete 
study data
Spreadsheet*     √
Intervention 
fidelity
Adherence to per protocol delivery of text 
messages
Checklist‡ √     
Follow- up with patients per protocol Checklist‡ √     
Provision of counselling when needed Checklist‡ √     
Arranging referrals when needed Checklist‡ √     
Intervention 
engagement
Participant response rate within a 48- hour 
window49
Checklist‡ √     
No of times participants initiate messaging Checklist‡ √     
Time of active participation in the study55 Checklist‡     √
*Track- sheet: Project leader will enter all data into tracking sheets.
†Analysis: postintervention analysis of sociodemographic and clinical data across study groups.
‡Checklist: The intervention facilitator and research assistants will have checklists.
PLHIV, people living with HIV.
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to detect definitive effect sizes, but any change in direc-
tion would likely inform the future definitive trial.
Data analysis
To assess the feasibility of the trial, a descriptive data anal-
ysis approach will be undertaken. Participant flow will be 
summarised, reporting the proportion of recently diag-
nosed PLHIV who were eligible to participate from the list 
of those who are new patients under the care of the VCT 
centre, and those of which who were reached, screened, 
enrolled and randomised, respectively. Following rando-
misation, the rate of retention of participants will be used 
to assess potential for bias and the representativeness of 
the final analytic sample. Baseline characteristics will be 
compared between participants and eligible PLHIV who 
did not participate utilising clinic files, using Cochran 
Mantel- Haenszel χ2 tests for categorical variables and 
Student’s t- tests for continuous variables. Comparisons 
will also be made between intervention versus compar-
ison participants to assess randomisation, and between 
those who completed the intervention vs those lost to 
follow- up. A descriptive analysis of the outcome measures 
for intervention fidelity, intervention engagement and 
acceptability will be summarised. All analyses will be 
conducted using the R programming software.
The pilot trial will be reported using Consolidated 
Standards of Reporting Trials guidelines on standards 
of reporting randomised trials. All randomised partic-
ipants will be included in analyses. We will perform 
both intention- to- treat and per- protocol analyses. 
Given the pilot nature of this study, all analyses will be 
non- confirmatory. To generate preliminary data on 
the efficacy of HamRaah, univariate logistic and linear 
regression models will be used for dichotomous (reten-
tion and viral suppression) and continuous (adherence 
and CD4 Cell count) outcomes respectively. For the main 
dichotomous outcome (%≥ 95% adherence after the 
6- month intervention), risk differences and 95% CIs will 
be calculated. Achieving undetectable viral load will be 
similarly treated as a dichotomous outcome. Estimates 
of effect sizes for the differences between HamRaah and 
comparison groups will be used to perform calculations 
of sample sizes needed for a future definitive randomised 
controlled trial. To examine interrelationships among 
adherence and other psychosocial measures, bivariate 
Pearson correlations will also be explored. Given the 
limited statistical power, subgroup analyses will be explor-
atory only.
The acceptability study aims to focus on participant 
perceptions regarding the cultural and logistic appro-
priateness of HamRaah, and the burden of the interven-
tion. The research question will aim to answer whether 
HamRaah fits the personal, cultural and social contexts 
of new PLHIV, and whether the intervention was useful in 
ways that may have not been captured via the quantitative 
measures.
The nested realist evaluation will use a theory- driven 
approach and aims to examine why, how, for whom, and 
in what context the intervention is effective. The process 
will be informed by the initial programme theory, which 
is depicted in figure 4 and was informed by an initial 
qualitative study. The theory highlights the resources 
that can be modified through mHealth during the life-
time of ART, and it guides how (if at all) HamRaah will 
change the context and impact these steps in a way that 
could explain the intervention mechanism(s) for future 
trials.
The realist evaluation and acceptability study will both 
be embedded into the intervention arm of the trial, and 
qualitative interviews and FGDs will begin following 
participants’ completion of the intervention.
All qualitative data will be managed through MAXQDA. 
The data sets will be synthesised drawing on the principles of 
realist evaluations, generating context- mechanism- outcome 
configurations to enrich and refine the initial programme 
theory. This will contribute to better understanding of the 
mechanism of HamRaah and the role of context.
In a sequential triangulation approach, the hypotheses 
arising from the realist and qualitative findings will be 
tested in a second quantitative step, using the collected 
psychosocial measures, for exploring preliminary changes 
on mediating factors. The results will inform future inves-
tigations in the planned larger trial.
Patient and public involvement
Decisions regarding the intervention, such as two- way 
versus one- way, and frequency of, messaging, were made 
in consultation with PLHIV and the healthcare team in 
the qualitative phase to ensure that the intervention is low 
burden and suited to context of PLHIV needs. Similarly, 
decisions regarding trial conduct were made in consulta-
tion with patients. These decisions included offering free 
viral load tests as a benefit of participation, optionality on 
which messaging application to receive HamRaah, and 
both online and offline means of completing the ques-
tionnaires. Moreover, research assistants, leading the 
recruitment, enrolment and interviewing of participants 
are members of the PLHIV community. Per the research 
plan, the results of the trial will be disseminated in a 
report format to all participants via mobile messaging, in 
the spirit of HamRaah.
Figure 4 Realist programme theory.
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The HIV epidemic in Iran is heavily concentrated among 
people who use drugs, sex workers, transgendered popu-
lations and men who have sex with men. In Iran, research 
conducted with such populations and approved by local 
ethics committee benefits from full confidentiality. Access 
to medical care is not restricted for these populations who 
are protected by doctor–patient confidentiality. However, 
special care and consideration needs to be applied in 
order to protect patient confidentiality, especially consid-
ering the limitations in controlling the faith of text 
messages. Messages may be read by persons other than 
the intended recipient, can easily be forwarded and could 
remain resident on unsecured devices for the lifetime 
of the technology. Text messages containing reminders 
to take medications, for example, could result in unin-
tended disclosure of a medical condition even without 
specifying any details. To address this issue, following 
extensive consultation with the local institution, it was 
decided that the study would exclude participants who 
do not consent to receiving HIV- related communication 
on their phones due to concerns regarding unintended 
disclosure. As such, the risk of such disclosure will be 
minimised for study purposes. Moreover, potential social 
harms will be investigated to arrange counselling services 
as needed. Finally, the following steps will be taken to 
further minimise these risks:
i. No direct mention of HIV will be included in the ini-
tial message. Only if patient initiates direct questions 
on HIV, would the counsellor follow- up with provid-
ing HIV- specific information. ii. Messaging interven-
tion will be delivered through WhatsApp, Telegram 
or Signal, which are fully encrypted. Participants will 
choose a nickname to be used for chatting with the 
counsellor.
ii. To safeguard patient privacy, the option is given to 
choose a pin, which they will share with the staff on 
initiation of conversation to ensure that counsellor is 
not in contact with a third party.
iii. Participants can choose to discontinue participation 
at any point, and the study team will be responsible to 
ensure no harm is inflicted on the study population 
as a result of their participation in the trial.
No financial rewards will be given for participation to 
avoid coercive appeal for participation. A free viral load 
test at the conclusion of the study will be offered as benefit 
of participation. A warm meal will be provided in appreci-
ation of participation on presenting for final assessment, 
focus groups and interviews. However, in light of the 
COVID-19 pandemic, arrangements to provide a meal- 
card for a food delivery service will be offered.
Ethical approval
The study has received ethical clearance from Tehran 
University of Medical Sciences and Oxford Tropical 
Research Ethics Committee. The funding for the study 
has been secured through the Tehran University of 
Medical Sciences research fund.
Data transfer and storage
Study data are collected and managed using REDCap 
tools hosted at Partners Healthcare.1 2 REDCap is a secure, 
SSL encrypted, web- based software platform designed to 
support data capture for research studies. The survey link 
is a singular URL to the survey, which does not track IP 
addresses, email addresses or any other identifying infor-
mation. No identifiable questions will be included in the 
survey items. The data will be stored in the secure servers 
of REDCap, and the anonymised data will be exported to 
the research group in the chosen file format.
FGDs and in- depth interviews will be recorded with 
the consent of participants. The informed consent forms 
will include participants’ full names and signatures, but 
these will not be collected by the administrator of the 
focus groups and/or interviews. As such, all recordings of 
the discussions and interviews will not contain personal 
identifiers, such as full names. The audio recordings of 
participants’ voices will be transcribed. However, the 
transcription process will deliberately not transcribe 
any of the identifying information, in the event that any 
personal identifiers are disclosed. As such, no informa-
tion with personal identifiers will be stored or accessible 
following transcription of the recordings.
All data, both from qualitative interviews and quantita-
tive surveys, will be accessible to the primary investigator, 
who will share deidentified data with coinvestigators as 
needed only for analysis purposes.
Dissemination
The results will be disseminated at several levels, including 
PLHIV, peer supporters, practitioners, researchers, health-
care organisations, and policy and programme stake-
holders. Annual reports to TUMS research committee 
will be provided, in addition to presentations at IRCHA 
for the local stakeholders and representatives from the 
community of PLHIV in Tehran. Dissemination will also 
include peer- reviewed journal publications and presenta-
tions at national and international conferences. It is also 
hoped that the results of the trial will be disseminated in 
a report format to all participants via mobile messaging, 
in the spirit of HamRaah.
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DISCUSSION
This study is the first to explore the potential of mHealth 
to improve PLHIV’s treatment adherence in a MENA 
country. Given the known relationship between adher-
ence to ART and viral load suppression,54 the results 
will further shed light on the potential of mHealth 
to suppress viral load within the first year of HIV diag-
nosis. The results of this study will provide important 
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information with respect to feasibility and acceptability of 
mHealth within the HIV care structure of Iran. Findings 
will inform the implementation of a larger definitive trial, 
which could apply a multicity design. The embedded 
realist evaluation will shed light on the mechanism of the 
intervention; how, for whom, in what context and why the 
programme is effective.
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Additional Information on the Research Setting: 
 
The infectious diseases unit of Imam Khomeini Hospital Complex (IKHC) includes 13 physicians, 
who are faculty members at TUMS and members of the Iranian Academy of Sciences, serving as 
advisors for health programming and guideline development. Additionally, 17 residents specialising in 
infectious diseases and 32 nurses staff the infectious diseases unit. The VCT centre, which is mainly 
focused on HIV and other sexually transmitted diseases, includes a team of four physicians and two 
counsellors. The Positive Club is under the oversight of the VCT centre. IRCHA and its 8 full-time 
researchers and research assistants collaborate with the VCT and the positive club.  
 
 
Additional Information on Routine Care:  
 
Patients are expected to visit the clinic monthly to receive free medication refills and clinical 
examinations. Counselling on adherence is offered to patients who miss monthly visits or report 
problems with medication adherence, viral suppression, or treatment resistance. As part of the routine 
care, a mandatory check-up with an infectious disease specialist is also offered every three months for 
patients with clinical signs of non-adherence or signs of irregular medication pick up. The Positive 
Club offers additional counselling and support, on referral, for PLHIV who are facing adherence or 
psychosocial difficulties. The intervention group will also receive these routine services, in addition to 
the HamRaah intervention, which includes independent counsellors to prevent risk of contamination. 
 
Additional Information on HamRaah Intervention: 
 
When contact is triggered, the counsellor will enquire about the problems the patient may be facing, 
or the reasons for missing doses. The counsellor will be selected from the pool of locally trained 
psychologists, most of whom receive CBT training, to ensure PLHIV are treated sensitively and 
professionally on the phone. As such, the intervention is not meant to provide CBT through 
messaging, but rather differentiate patients who may need a one-time over-the-phone support from 
those who need to be referred for additional and more long-term support. However, if long-term 
support is needed, the counsellor, familiar with IKHC resources, will refer the patient according and 
tailored to his/her needs to further services, in such a way to ensure HamRaah is boosting access to 
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available healthcare capacities. For example, patients who are facing mental health challenges will be 
encouraged to accept a referral to counselling to help patients address any emotional or cognitive 
barriers to ART use. Additionally, they could be linked to the peer-support offered at the Positive 
Club, which also provides educational, motivational, and skill-building classes, and where both PLHIV 
and trained psychologists operate a variety of weekly classes to help patients address barriers to 
adherence through problem solving and encouraging good habit formation. In cases where medical 
counselling and clinical treatment are necessary, appropriate referrals are offered.  
 
Thus, HamRaah aims to promote adherence to ART as primary outcome. It also aims to streamline 
the process through which newly diagnosed PLHIV access available health services that meet their 
needs in a timely window, before critical care becomes necessary.  The weekly check-in schedule could 
also prevent prolonged gaps in adherence that increase the risk of viral rebound. It also seeks to 
promote good medication-taking habits to achieve optimal longer-term outcomes.  
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